Lake Street raised the firm's price target on Insight Molecular Diagnostics to $12 from $8 and keeps a Buy rating on the shares. With Insight having completed a $26M offering last week, cash on hand is now secured beyond a potential approval later this year, notes the analyst, who expects an FDA submission for GraftAssureDx in the coming weeks to be a catalyst for shares.
